Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of ...
Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...
The autologous CAR-T cell therapy MB-105 has received regenerative medicine advanced therapy (RMAT) designation from the FDA ...
In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...
International collaboration is crucial for enhancing rural cancer care, with shared experiences and solutions from across the ...
The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...
Ziftomenib is the first Menin inhibitor approved for relapsed or refractory mutant nucleophosmin 1 acute myeloid leukemia, showing promising efficacy in clinical trials. The phase 2 KOMET-001 trial ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback